Phantom criteria for qualification of brain FDG and amyloid PET across different cameras

[1]  E. Siemers,et al.  Delayed-start analysis: Mild Alzheimer's disease patients in solanezumab trials, 3.5 years , 2015, Alzheimer's & dementia.

[2]  W. Jagust,et al.  The Alzheimer's Disease Neuroimaging Initiative 2 PET Core: 2015 , 2015, Alzheimer's & Dementia.

[3]  A. Joshi,et al.  Imaging characteristics and safety of florbetapir (18F) in Japanese healthy volunteers, patients with mild cognitive impairment and patients with Alzheimer’s disease , 2015, Annals of Nuclear Medicine.

[4]  Jae Seung Kim,et al.  Efficacy of [18F]flutemetamol in the Japanese population , 2014 .

[5]  E. Siemers,et al.  Phase 3 trials of solanezumab for mild-to-moderate Alzheimer's disease. , 2014, The New England journal of medicine.

[6]  Takashi Kato,et al.  Equal sensitivity of early and late scans after injection of FDG for the detection of Alzheimer pattern: an analysis of 3D PET data from J-ADNI, a multi-center study , 2013, Annals of Nuclear Medicine.

[7]  D. Brooks,et al.  The prognostic value of amyloid imaging , 2012, European Journal of Nuclear Medicine and Molecular Imaging.

[8]  M. Mintun,et al.  Performance Characteristics of Amyloid PET with Florbetapir F 18 in Patients with Alzheimer's Disease and Cognitively Normal Subjects , 2012, The Journal of Nuclear Medicine.

[9]  Victor L. Villemagne,et al.  Brain Amyloid Imaging , 2011, The Journal of Nuclear Medicine.

[10]  Karl Herholz,et al.  Evaluation of a Calibrated 18F-FDG PET Score as a Biomarker for Progression in Alzheimer Disease and Mild Cognitive Impairment , 2011, The Journal of Nuclear Medicine.

[11]  J. Morris,et al.  The diagnosis of dementia due to Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer's disease , 2011, Alzheimer's & Dementia.

[12]  M. Modat,et al.  The importance of appropriate partial volume correction for PET quantification in Alzheimer’s disease , 2011, European Journal of Nuclear Medicine and Molecular Imaging.

[13]  E. Salmon,et al.  18F‐flutemetamol amyloid imaging in Alzheimer disease and mild cognitive impairment: A phase 2 trial , 2010, Annals of neurology.

[14]  James Robert Brašić,et al.  In Vivo Imaging of Amyloid Deposition in Alzheimer Disease Using the Radioligand 18F-AV-45 (Flobetapir F 18) , 2010, Journal of Nuclear Medicine.

[15]  Takeshi Iwatsubo,et al.  Japanese Alzheimer's Disease Neuroimaging Initiative: Present status and future , 2010, Alzheimer's & Dementia.

[16]  T. Yen,et al.  Whole-body biodistribution and brain PET imaging with [18F]AV-45, a novel amyloid imaging agent--a pilot study. , 2010, Nuclear medicine and biology.

[17]  W. Jagust,et al.  The Alzheimer's Disease Neuroimaging Initiative positron emission tomography core , 2010, Alzheimer's & Dementia.

[18]  L. Thurfjell,et al.  Phase 1 Study of the Pittsburgh Compound B Derivative 18F-Flutemetamol in Healthy Volunteers and Patients with Probable Alzheimer Disease , 2009, Journal of Nuclear Medicine.

[19]  Jeffrey A. Fessler,et al.  Reducing between scanner differences in multi-center PET studies , 2009, NeuroImage.

[20]  R. Vandenberghe,et al.  Whole-Body Biodistribution and Radiation Dosimetry of 18F-GE067: A Radioligand for In Vivo Brain Amyloid Imaging , 2009, Journal of Nuclear Medicine.

[21]  C. Rowe,et al.  Radiation Dosimetry of β-Amyloid Tracers 11C-PiB and 18F-BAY94-9172 , 2009, Journal of Nuclear Medicine.

[22]  Nick C Fox,et al.  The Alzheimer's disease neuroimaging initiative (ADNI): MRI methods , 2008, Journal of magnetic resonance imaging : JMRI.

[23]  C. Rowe,et al.  Imaging of amyloid β in Alzheimer's disease with 18F-BAY94-9172, a novel PET tracer: proof of mechanism , 2008, The Lancet Neurology.

[24]  Christopher C Rowe,et al.  Visual Assessment Versus Quantitative Assessment of 11C-PIB PET and 18F-FDG PET for Detection of Alzheimer's Disease , 2007, Journal of Nuclear Medicine.

[25]  S. DeKosky,et al.  Simplified quantification of Pittsburgh Compound B amyloid imaging PET studies: a comparative analysis. , 2005, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[26]  Joseph V. Hajnal,et al.  A robust method to estimate the intracranial volume across MRI field strengths (1.5T and 3T) , 2010, NeuroImage.

[27]  C. Jack,et al.  Ways toward an early diagnosis in Alzheimer’s disease: The Alzheimer’s Disease Neuroimaging Initiative (ADNI) , 2005, Alzheimer's & Dementia.

[28]  S. DeKosky,et al.  Kinetic Modeling of Amyloid Binding in Humans using PET Imaging and Pittsburgh Compound-B , 2005, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[29]  Kazuyoshi Yajima,et al.  Brain FDG PET study of normal aging in Japanese: effect of atrophy correction , 2005, European Journal of Nuclear Medicine and Molecular Imaging.

[30]  W. Klunk,et al.  Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound‐B , 2004, Annals of neurology.

[31]  et al.,et al.  Discrimination between Alzheimer Dementia and Controls by Automated Analysis of Multicenter FDG PET , 2002, NeuroImage.

[32]  G. Alexander,et al.  Positron emission tomography in evaluation of dementia: Regional brain metabolism and long-term outcome. , 2001, JAMA.

[33]  M. Hays,et al.  A mathematical model for the distribution of fluorodeoxyglucose in humans. , 1999, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[34]  R. Koeppe,et al.  A diagnostic approach in Alzheimer's disease using three-dimensional stereotactic surface projections of fluorine-18-FDG PET. , 1995, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[35]  J C Mazziotta,et al.  Assessment of Accuracy of PET Utilizing a 3-D Phantom to Simulate the Activity Distribution of [18F]Fluorodeoxyglucose Uptake in the Human Brain , 1991, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[36]  Tobias J. Hagge,et al.  Physics , 1929, Nature.

[37]  Hiroyuki Nishida,et al.  Optimization of image reconstruction conditions with phantoms for brain FDG and amyloid PET imaging , 2015, Annals of Nuclear Medicine.

[38]  Standard PET imaging protocols and phantom test procedures and criteria : executive summary , 2014 .